May 1, 2024EP EuropaceOpen Access

Ablation of hemodynamically unstable ventricular tachycardia guided by ultra-high density pacemapping and PASO correlation map, a multi-center clinical trial

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial demonstrates reduced recurrent ventricular tachycardia in patients with ischemic heart disease, suggesting a novel mapping approach.

Patients who underwent ultra-high density pace-mapping ablation exhibited a lower cumulative probability of recurrent ventricular tachycardia events.
At one-year follow-up, only 17% of ablated patients experienced VT/VF recurrence, compared to 69% in the control group.
This prospective multi-center clinical trial involved 30 patients with ischemic heart disease who were clinically indicated for ablation procedures for VT management; follow-up data were meticulously collected post-procedure to evaluate effectiveness and safety outcomes in comparison to a matched control group from the RAID trial, highlighting the effectiveness of the intervention in achieving favorable results for those undergoing ablation strategy specially tailored using pace-mapping and PASO algorithm methodology to create a more precise identification of the essential conduction pathways within the heart's electrical system that facilitate arrhythmic events, significantly outweighing outcomes achieved through conventional medical management alone. Their results yield substantial clinical implications regarding advancements in VT treatment protocols and the safety provided by comprehensive procedures that ensure effective patient recovery and quality of life post-ablation.

Huang et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates reduced recurrent ventricular tachycardia in patients with ischemic heart disease, suggesting a novel mapping approach.